Go to
current issue
-
Is allogeneic transplantation the preferred therapy for older patients with acute myeloid leukemia? Haematologica (IF 9.941) Pub Date : 2021-10-14 Arnold Ganser
Not available.
-
INTERFERing T-ALL progression: a multifaceted therapy. Haematologica (IF 9.941) Pub Date : 2021-10-14 Daniel Herranz
Not available.
-
Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis. Haematologica (IF 9.941) Pub Date : 2021-10-14 Marcelo Capra, Thomas Martin, Philippe Moreau, Ross Baker, Ludek Pour, Chang-Ki Min, Xavier Leleu, Mohamad Mohty, Marta Reinoso Segura, Mehmet Turgut, Richard LeBlanc, Marie-Laure Risse, Laure Malinge, Sandrine Schwab, Meletios Dimopoulos
Renal impairment (RI) is common in patients with multiple myeloma (MM) and new therapies that can improve renal function are needed. The Phase 3 IKEMA study (NCT03275285) investigated isatuximab (Isa) with carfilzomib and dexamethasone (Kd) vs Kd in relapsed MM. This subgroup analysis examined results from patients with RI, defined as estimated glomerular filtration rate.
-
Profound systemic alteration of the immune phenotype and an immunoglobulin switch in Erdheim-Chester disease in a single-center of 78 patients. Haematologica (IF 9.941) Pub Date : 2021-10-14 Fleur Cohen Aubart, Lucie Poupel, Flora Saint-Charles, Frederic Charlotte, Youssef Arsafi, Eric Frisdal, Damien Roos-Weil, Jean-Francois Emile, Zahir Amoura, Maryse Guerin, Philippe Lesnik, Julien Haroche, Wilfried Le Goff
Erdheim-Chester disease (ECD) is a rare, systemic, non-Langerhans cell histiocytosis neoplasm, which is characterized by the infiltration of CD63+ CD1a- histiocytes in multiple tissues. The BRAFV600E mutation is frequently present in individuals with ECD and has been detected in hematopoietic stem cells and immune cells from the myeloid and systemic compartments. Immune cells and proinflammatory cytokines
-
Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukemia: results of the NCRI acute myeloid leukemia 16 trial. Haematologica (IF 9.941) Pub Date : 2021-10-14 Nigel H Russell, Robert K Hills, Abin Thomas, Ian Thomas, Lars Kjeldsen, Mike Dennis, Charles Craddock, Sylvie Freeman, Richard E Clark, Alan K Burnett
Reduced Intensity Conditioning (RIC) transplantation is increasingly offered to older patients with acute myeloblastic leukemia (AML). We have previously shown that a RIC allograft, particularly from a sibling donor is beneficial in intermediate risk patients aged 35-65 years. We here present analyses from the NCRI AML16 trial extending this experience to older patients aged 60-70 inclusive lacking
-
Direct and indirect anti-leukemic properties of Activity-on-Target interferons for the treatment of T-cell acute lymphoblastic leukemia. Haematologica (IF 9.941) Pub Date : 2021-10-14 Steven Goossens, Anje Cauwels, Tim Pieters, Renate De Smedt, Sara T'Sas, André Almeida, Willem Daneels, Pieter Van Vlierberghe, Jan Tavernier
Not available.
-
First report of inherited protein S deficiency caused by paternal PROS1 mosaicism. Haematologica (IF 9.941) Pub Date : 2021-10-14 Satomi Nagaya, Keiko Maruyama, Atsushi Watanabe, Makiko Meguro-Horike, Yuta Imai, Yuki Hiroshima, Shin-Ichi Horike, Koichi Kokame, Eriko Morishita
Not available.
-
Treatment with ibrutinib does not induce a TP53 clonal evolution in chronic lymphocytic leukemia. Haematologica (IF 9.941) Pub Date : 2021-10-14 Luciana Cafforio, Sara Raponi, Luca Vincenzo Cappelli, Caterina Ilari, Roberta Soscia, Maria Stefania De Propris, Paola Mariglia, Gian Matteo Rigolin, Antonella Bardi, Nadia Peragine, Alfonso Piciocchi, Valentina Arena, Francesca Romana Mauro, Antonio Cuneo, Anna Guarini, Robin Foa, Ilaria Del Giudice
Not available.
-
Critical role of peroxisome proliferator-activated receptor α in promoting platelet hyperreactivity and thrombosis under hyperlipidemia. Haematologica (IF 9.941) Pub Date : 2021-10-07 Li Li, Jiawei Zhou, Shuai Wang, Lei Jiang, Xiaoyan Chen, Yangfan Zhou, Jingke Li, Jingqi Shi, Pu Liu, Zheyue Shu, Frank J Gonzalez, Aiming Liu, Hu Hu
Platelet hyperreactivity and increased atherothrombotic risk are specifically associated with dyslipidemia. Peroxisome proliferator-activated receptor alpha (PPARα) is an important regulator of lipid metabolism. It was suggested to affect both thrombosis and hemostasis, yet the underlying mechanisms are not well understood. In this study, the role and mechanism of PPARα in platelet activation and thrombosis
-
Signal transduction pathway involved in platelet activation in immune thrombotic thrombocytopenia after COVID-19 vaccination. Haematologica (IF 9.941) Pub Date : 2021-10-07 Roberta Misasi, Antonella Capozzi, Gloria Riitano, Serena Recalchi, Valeria Manganelli, Vincenzo Mattei, Agostina Longo, Manuela De Michele, Tina Garofalo, Fabio M Pulcinelli, Maurizio Sorice
Not available.
-
Integrating genetic and epigenetic factors in chronic myeloid leukemia risk assessment: toward gene expression-based biomarkers. Haematologica (IF 9.941) Pub Date : 2021-10-07 Vaidehi Krishnan, Dennis Dong Hwan Kim, Timothy P Hughes, Susan Branford, S Tiong Ong
Cancer treatment is constantly evolving from a one-size-fits-all towards bespoke approaches for each patient. In certain solid cancers, including breast and lung, tumor genome profiling has been incorporated into therapeutic decision-making. For chronic phase (CP) chronic myeloid leukemia (CML), while tyrosine kinase inhibitor (TKI) therapy is the standard treatment, current clinical scoring systems
-
Expanding approaches to detect clonal hematopoiesis. Haematologica (IF 9.941) Pub Date : 2021-09-30 M A Wasay Khan,Alexander G Bick
Not available.
-
Utility of plasma cell-free DNA for de novo detection and quantification of clonal hematopoiesis. Haematologica (IF 9.941) Pub Date : 2021-09-30 Fernanda Gutierrez-Rodrigues,Isabel Beerman,Emma M Groarke,Bhavisha A Patel,Nina Spitofsky,Laura W Dillon,Diego Quinones Raffo,Christopher S Hourigan,Sachiko Kajigaya,Luigi Ferrucci,Neal S Young
Although cell-free DNA (cfDNA) tests have emerged as a potential non-invasive alterative for bone marrow biopsies in monitoring of clonal hematopoiesis (CH) in hematologic diseases, whether commercial cfDNA assays can be implemented for de novo CH detection and quantification in place of blood cells is uncertain. In this study, peripheral plasma cfDNA samples available from patients with aplastic anemia
-
Ikaros deficiency is associated with aggressive BCR-ABL1 B cell precursor acute lymphoblastic leukemia independent of the lineage and developmental origin. Haematologica (IF 9.941) Pub Date : 2021-09-30 Célestine Simand,Céline Keime,Aurélie Cayé,Chloé Arfeuille,Marie Passet,Rathana Kim,Hélène Cavé,Emmanuelle Clappier,Philippe Kastner,Susan Chan,Beate Heizmann
Not available.
-
Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients. Haematologica (IF 9.941) Pub Date : 2021-09-30 Jennifer R Brown,John C Byrd,Paolo Ghia,Jeff P Sharman,Peter Hillmen,Deborah M Stephens,Clare Sun,Wojciech Jurczak,John M Pagel,Alessandra Ferrajoli,Priti Patel,Lin Tao,Nataliya Kuptsova-Clarkson,Javid Moslehi,Richard R Furman
Cardiovascular (CV) toxicities of the Bruton tyrosine kinase (BTK) inhibitor ibrutinib may limit use of this effective therapy in patients with chronic lymphocytic leukemia (CLL). Acalabrutinib is a second-generation BTK inhibitor with greater BTK selectivity. This analysis characterizes pooled CV adverse events (AEs) data in patients with CLL who received acalabrutinib monotherapy in clinical trials
-
Planned withdrawal of dexamethasone after pomalidomide low dose dexamethasone induction for lenalidomide refractory multiple myeloma (ALLG MM14). Haematologica (IF 9.941) Pub Date : 2021-09-30 Anna Kalff,Tiffany Khong,Malarmathy Ramachandran,P Joy Ho,Peter Mollee,James D'Rozario,Kerry Taylor,Jane Estell,Sam Norton,Roslyn Kemp,Andrew J Mitchell,John Reynolds,Nola Kennedy,Hang Quach,Andrew Spencer
Not available.
-
For older adults with hematologic malignancies, a comprehensive geriatric assessment matters. Haematologica (IF 9.941) Pub Date : 2021-09-23 Raul Cordoba
Not available.
-
Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia. Haematologica (IF 9.941) Pub Date : 2021-09-23 Srdan Verstovsek, Ruben Mesa, Moshe Talpaz, Jean-Jacques Kiladjian, Claire N Harrison, Stephen T Oh, Alessandro M Vannucchi, Raajit Rampal, Bart L Scott, Sarah A Buckley, Adam R Craig, Karisse Roman-Torres, John O Mascarenhas
Thrombocytopenia is common in patients with myelofibrosis and is a well-established adverse prognostic factor. Both of the approved Janus kinase (JAK) inhibitors, ruxolitinib and fedratinib, can worsen thrombocytopenia and have not been evaluated in patients with severe thrombocytopenia (.
-
Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: results from the phase 3, placebocontrolled QUAZAR AML-001 trial. Haematologica (IF 9.941) Pub Date : 2021-09-23 Gail J Roboz, Hartmut Dohner, Christopher Pocock, Herve Dombret, Farhad Ravandi, Jun Ho Jang, Dominik Selleslag, Jiři Mayer, Uwe M Martens, Jane Liesveld, Teresa Bernal, Ming Chung Wang, Peiwen Yu, Ling Shi, Shien Guo, Ignazia La Torre, Barry Skikne, Qian Dong, Julia Braverman, Salem Abi Nehme, C L Beach, Andrew H Wei
Not available.
-
Randomized controlled trial of geriatric consultation versus standard care in older adults with hematologic malignancies. Haematologica (IF 9.941) Pub Date : 2021-09-23 Clark DuMontier, Hajime Uno, Tammy Hshieh, Guohai Zhou, Richard Chen, Emily S Magnavita, Lee Mozessohn, Houman Javedan, Richard M Stone, Robert J Soiffer, Jane A Driver, Gregory A Abel
We conducted a randomized controlled trial in older adults with hematologic malignancies to determine the impact of geriatrician consultation embedded in our oncology clinic alongside standard care. From February 2015 to May 2018, transplant-ineligible patients age ii75 years who presented for initial consultation for lymphoma, leukemia, or multiple myeloma at Dana-Farber Cancer Institute (Boston,
-
In utero thirdhand smoke exposure modulates platelet function in a sex-dependent manner. Haematologica (IF 9.941) Pub Date : 2021-09-16 Hamdy A Ali, Ahmed B Alarabi, Zubair A Karim, Victor Rodriguez, Keziah R Hernandez, Patricia A Lozano, Medhat S El-Halawany, Fatima Z Alshbool, Fadi T Khasawneh
Not available.
-
Single platelet and megakaryocyte morpho-dynamics uncovered by multicolor reporter mouse strains in vitro and in vivo. Haematologica (IF 9.941) Pub Date : 2021-09-16 Leo Nicolai, Rainer Kaiser, Raphael Escaig, Marie-Louise Hoffknecht, Afra Anjum, Alexander Leunig, Joachim Pircher, Andreas Ehrlich, Michael Lorenz, Hellen Ishikawa-Ankerhold, William C Aird, Steffen Massberg, Florian Gaertner
Visualizing cell behavior and effector function on a single cell level has been crucial for understanding key aspects of mammalian biology. Due to their small size, large number and rapid recruitment into thrombi, there is a lack of data on fate and behavior of individual platelets in thrombosis and hemostasis. Here we report the use of platelet lineage restricted multi-color reporter mouse strains
-
Lower respiratory tract infection with Staphylococcus aureus in sickle-cell adult patients with severe acute chest syndrome - the STAPHACS Study. Haematologica (IF 9.941) Pub Date : 2021-09-16 Alexandre Elabbadi, Guillaume Voiriot, Anne Tristan, Aude Gibelin, Charlotte Verdet, Michel Djibré, Aline Santin, Etienne-Marie Jutant, Julien Lopinto, François Vandenesch, François Lionnet, Muriel Fartoukh
Not available.
-
Targeting Wnt signaling in acute myeloid leukemia stem cells. Haematologica (IF 9.941) Pub Date : 2021-09-16 Felice Pepe, Marius Bill, Dimitrios Papaioannou, Malith Karunasiri, Allison Walker, Eric Naumann, Katiri Snyder, Parvathi Ranganathan, Adrienne Dorrance, Ramiro Garzon
Not available.
-
Elastic compression stockings for prevention of the post-thrombotic syndrome in patients with and without residual vein thrombosis and/or popliteal valve reflux. Haematologica (IF 9.941) Pub Date : 2021-09-09 Paolo Prandoni, Anthonie Wa Lensing, Martin H Prins, Sabina Villalta, Raffaele Pesavento, Daniela Tormene, Franco Noventa, Gualtiero Palareti
Not available.
-
In classical Hodgkin lymphoma the combination of the CCR5 antagonist maraviroc with trabectedin synergizes, enhances DNA damage and decreases 3D tumor-stroma heterospheroid viability. Haematologica (IF 9.941) Pub Date : 2021-09-09 Naike Casagrande, Cinzia Borghese, Donatella Aldinucci
Not available.
-
Hepcidin regulation in Kenyan children with severe malaria and non-typhoidal Salmonella bacteremia. Haematologica (IF 9.941) Pub Date : 2021-09-09 Kelvin M Abuga, John Muthii Muriuki, Sophie M Uyoga, Kennedy Mwai, Johnstone Makale, Reagan M Mogire, Alex W Macharia, Shebe Mohammed, Esther Muthumbi, Salim Mwarumba, Neema Mturi, Philip Bejon, J Anthony G Scott, Manfred Nairz, Thomas N Williams, Sarah H Atkinson
Malaria and invasive non-typhoidal Salmonella (NTS) are life-threatening infections that often co-exist in African children. The iron-regulatory hormone hepcidin is highly upregulated during malaria and controls the availability of iron, a critical nutrient for bacterial growth. We investigated the relationship between Plasmodium falciparum malaria and NTS bacteremia in all pediatric admissions aged
-
Stored blood has compromised oxygen unloading kinetics that can be normalized with rejuvenation and predicted from corpuscular side-scatter. Haematologica (IF 9.941) Pub Date : 2021-09-09 Killian Donovan, Athinoula Meli, Francesca Cendali, Kyung Chan Park, Rebecca Cardigan, Simon Stanworth, Stuart McKechnie, Angelo D'Alessandro, Peter A Smethurst, Pawel Swietach
Not available.
-
Vecabrutinib inhibits B-cell receptor signal transduction in chronic lymphocytic leukemia cell types with wild-type or mutant Bruton's tyrosine kinase. Haematologica (IF 9.941) Pub Date : 2021-09-09 Burcu Aslan, Stefan Edward Hubner, Judith A Fox, Pietro Taverna, William G Wierda, Steven M Kornblau, Varsha Gandhi
Not available.
-
Dose-adjusted EPOCH-Rituximab or intensified B-NHL therapy for pediatric primary mediastinal large B-cell lymphoma. Haematologica (IF 9.941) Pub Date : 2021-09-09 Fabian Knörr, Martin Zimmermann, Andishe Attarbaschi, Edita Kabíčková, Britta Maecker-Kolhoff, Stephanie Ruf, Ingrid Kühnle, Martin Ebinger, Anne-Kathrin Garthe, Ingrid Simonitsch-Klupp, Ilske Oschlies, Wolfram Klapper, Birgit Burkhardt, Wilhelm Woessmann
Not available.
-
Increased double-negative αβ+ T-cells reveal adult-onset autoimmune lymphoproliferative syndrome in a patient with IgG4-related disease. Haematologica (IF 9.941) Pub Date : 2021-09-02 Nivaz Brar, Michael A Spinner, Matthew C Baker, Ranjana H Advani, Yasodha Natkunam, David B Lewis, Oscar Silva
Not available.
-
Platelet activation and modulation in thrombosis with thrombocytopenia syndrome associated with ChAdO×1 nCov-19 vaccine. Haematologica (IF 9.941) Pub Date : 2021-09-02 Mariangela Scavone, Bianca Clerici, Simone Birocchi, Tatiana Mencarini, Mariagrazia Calogiuri, Claudia Ghali, Daniele Prati, Silvia Bozzi, Paolo Villa, Marco Cattaneo, Gian Marco Podda
Not available.
-
Diabetes mellitus and risk of plasma cell and lymphoproliferative disorders in 94,579 cases and 368,348 matched controls. Haematologica (IF 9.941) Pub Date : 2021-09-02 Urvi A Shah, Sæmundur Rögnvaldsson, Andriy Derkach, Magnus Björkholm, Ingemar Turesson, Yael David, Malin Hultcrantz, Carlyn Tan, Hani Hassoun, Neha Korde, Alexander Lesokhin, Sham Mailankody, Sigurður Yngvi Kristinsson, C Ola Landgren
Not available.
-
Preventing central nervous system spread in diffuse large B-cell lymphoma - novel approaches needed. Haematologica (IF 9.941) Pub Date : 2021-09-01 Mark Roschewski
-
Images from the Haematologica Atlas of Hematologic Cytology: primary myelofibrosis, micromegakaryocytic transformation. Haematologica (IF 9.941) Pub Date : 2021-09-01 Rosangela Invernizzi
-
Immune thrombocytopenia following vaccination during the COVID-19 pandemic. Haematologica (IF 9.941) Pub Date : 2021-08-26 Philip Young-Ill Choi, Danny Hsu, Huyen Anh Tran, Chee Wee Tan, Anoop Enjeti, Vivien Mun Yee Chen, Beng Hock Chong, Jennifer Curnow, Dominic Pepperell, Robert Bird
Not available.
-
Immune thrombocytopenia: vaccination does not equal causation. Haematologica (IF 9.941) Pub Date : 2021-08-26 Allyson Pishko, Adam Cuker
Not available.
-
Not all mismatches are equal: importance of alloreactivity direction. Haematologica (IF 9.941) Pub Date : 2021-08-26 Jacinta Perram, Nada Hamad
Not available.
-
Allogeneic hematopoietic cell transplantation outcomes in patients with Richter's transformation. Haematologica (IF 9.941) Pub Date : 2021-08-26 Haesook T Kim,Peter O Baker,Erin Parry,Matthew Davids,Edwin P Alyea,Vincent T Ho,Corey Cutler,John Koreth,Mahasweta Gooptu,Rizwan Romee,Sarah Nikiforow,Joseph H Antin,Jerome Ritz,Robert J Soiffer,Catherine J Wu,Jennifer R Brown
-
Refined HLA-DPB1 mismatch with molecular algorithms predicts outcomes in hematopoietic stem cell transplantation. Haematologica (IF 9.941) Pub Date : 2021-08-26 Jun Zou, Piyanuch Kongtim, Betül Oran, Vasilis Kosmoliaptsis, Yudith Carmazzi, Junsheng Ma, Liang Li, Gabriela Rondon, Samer Srour, Hannah C Copley, David Partlow, Stefan O Ciurea, Uri Greenbaum, Qing Ma, Elizabeth J Shpall, Richard E Champlin, Kai Cao
HLA-DPB1 mismatches between donor and recipient are commonly seen in allogeneic hematopoietic stem cell transplantation (HSCT) from an unrelated donor. HLA-DPB1 mismatch, conventionally determined by the similarity of the T-cell epitope (TCE), is associated with an increased risk of acute graft-versus-host disease (aGVHD) and a decreased risk of disease relapse. We investigated the clinical impact
-
BET inhibitors enhance embryonic and fetal globin expression in erythroleukemia cell lines. Haematologica (IF 9.941) Pub Date : 2021-08-26 John Z Cao, Kristina Bigelow, Amittha Wickrema, Lucy A Godley
Not available.
-
Melphalan dose intensity for autologous stem cell transplantation in multiple myeloma. Haematologica (IF 9.941) Pub Date : 2021-08-19 Samer A Srour, Denái R Milton, Qaiser Bashir, Yago Nieto, Neeraj Saini, May Daher, Jeremy Ramdial, Jin Im, Chitra Hosing, Ruby Delgado, Elisabet Manasanch, Hans C Lee, Sheeba Thomas, Greg Kaufman, Krina Patel, Uday Popat, Donna Weber, Robert Orlowski, Elizabeth Shpall, Richard E Champlin, Muzaffar H Qazilbash
Not available.
-
Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. Haematologica (IF 9.941) Pub Date : 2021-08-19 Johannes Duell, Kami J. Maddocks, Eva González-Barca, Wojciech Jurczak, Anna Marina Liberati, Sven De Vos, Zsolt Nagy, Aleš Obr, Gianluca Gaidano, Pau Abrisqueta, Nagesh Kalakonda, Marc André, Martin Dreyling, Tobias Menne, Olivier Tournilhac, Marinela Augustin, Andreas Rosenwald, Maren Dirnberger-Hertweck, Johannes Weirather, Sumeet Ambarkhane, Gilles Salles
Not available.
-
Interactions of adenoviruses with platelets and coagulation and the vaccine-associated autoimmune thrombocytopenia thrombosis syndrome. Haematologica (IF 9.941) Pub Date : 2021-08-19 Paolo Gresele, Stefania Momi, Rossella Marcucci, Francesco Ramundo, Valerio De Stefano, Armando Tripodi
The Covid-19 pandemic has heavily impacted global health and economy and vaccination remains the primary way of controlling the infection. During the ongoing vaccination campaign some unexpected thrombotic events have emerged in subjects who recently received the AstraZeneca Vaxzevria vaccine or the Johnson and Johnson (Janssen) vaccine, two adenovirus vector-based vaccines. Epidemiological studies
-
Biallelic mutations in the SARS2 gene presenting as congenital sideroblastic anemia. Haematologica (IF 9.941) Pub Date : 2021-08-19 Elia Colin, Geneviève Courtois, Chantal Brouzes, Juliette Pulman, Marion Rabant, Agnès Rötig, Hélène Taffin, Mathilde Lion-Lambert, Sylvie Fabrega, Lydie Da Costa, Mariane De Montalembert, Rémi Salomon, Olivier Hermine, Lucile Couronné
Not available.
-
Establishment of a Bernard-Soulier syndrome model in zebrafish. Haematologica (IF 9.941) Pub Date : 2021-08-19 Qing Lin, Riyang Zhou, Panpan Meng, Liangliang Wu, Lian Yang, Wenyu Liu, Jiaye Wu, Yuhuan Cheng, Linjuan Shi, Yiyue Zhang
Platelets play an essential role in thrombosis and hemostasis. Abnormal hemostasis can cause spontaneous or severe post-traumatic bleeding. Bernard-Soulier syndrome (BSS) is a rare inherited bleeding disorder caused by a complete quantitative deficiency in the GPIb-IX-V complex. Multiple mutations in GP9 lead to the clinical manifestation of BSS. Understanding the roles and underlying mechanisms of
-
Platelet dysfunction in platelet-type von Willebrand disease due to the constitutive triggering of the Lyn-PECAM1 inhibitory pathway. Haematologica (IF 9.941) Pub Date : 2021-08-19 Loredana Bury, Emanuela Falcinelli, Anna Maria Mezzasoma, Giuseppe Guglielmini, Stefania Momi, Paolo Gresele
Platelet-type von Willebrand disease (PT-VWD) is an inherited platelet disorder characterized by macrothrombocytopenia and mucocutaneous bleeding, of variable severity, due to gain-of-function variants of GP1BA conferring to glycoprotein Ibα (GPIbα) enhanced affinity for von Willebrand factor (VWF). The bleeding tendency is conventionally attributed to thrombocytopenia and large VWF-multimers depletion
-
Total metabolic tumor volume as a survival predictor for patients with diffuse large B-cell lymphoma in the GOYA study. Haematologica (IF 9.941) Pub Date : 2021-08-19 Lale Kostakoglu, Federico Mattiello, Maurizio Martelli, Laurie H Sehn, David Belada, Chiara Ghiggi, Neil Chua, Eva González-Barca, Xiaonan Hong, Antonio Pinto, Yuankai Shi, Yoichi Tatsumi, Christopher Bolen, Andrea Knapp, Gila Sellam, Tina Nielsen, Deniz Sahin, Umberto Vitolo, Marek Trněný
This retrospective analysis of the phase III GOYA study investigated the prognostic value of baseline metabolic tumor volume parameters and maximum standardized uptake values for overall and progression-free survival in treatment-naïve diffuse large B-cell lymphoma. Baseline total metabolic tumor volume (determined for tumors >1 mL using a threshold of 1.5 times the mean liver standardized uptake value
-
Therapeutic targeting of endoplasmic reticulum stress in acute graft-versus-host disease. Haematologica (IF 9.941) Pub Date : 2021-08-19 Eileen Haring, Geoffroy Andrieux, Franziska M Uhl, Máté Krausz, Michele Proietti, Barbara Sauer, Philipp R Esser, Stefan F Martin, Dietmar Pfeifer, Annette Schmitt-Graeff, Justus Duyster, Natalie Köhler, Bodo Grimbacher, Melanie Boerries, Konrad Aumann, Robert Zeiser, Petya Apostolova
Acute graft-versus-host disease (GVHD) is a life-threatening complication of allogeneic hematopoietic cell transplantation (allo-HCT), a potentially curative treatment for leukemia. Endoplasmic reticulum (ER) stress occurs when the protein folding capacity of the ER is oversaturated. How ER stress modulates tissue homeostasis in the context of alloimmunity is not well understood. We show that ER stress
-
Whole-genome profiling of primary cutaneous anaplastic large cell lymphoma. Haematologica (IF 9.941) Pub Date : 2021-08-12 Armando N Bastidas Torres, Rutger C Melchers, Liana Van Grieken, Jacoba J Out-Luiting, Hailiang Mei, Cedrick Agaser, Thomas B Kuipers, Koen D Quint, Rein Willemze, Maarten H Vermeer, Cornelis P Tensen
Primary cutaneous anaplastic large cell lymphoma (pcALCL), a hematological neoplasm caused by skin-homing CD30+ malignant T cells, is part of the spectrum of primary cutaneous CD30+ lymphoproliferative disorders. To date, only a small number of molecular alterations have been described in pcALCL, and so far, no clear unifying theme that could explain the pathogenetic origin of the disease has emerged
-
Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease status. Haematologica (IF 9.941) Pub Date : 2021-08-12 David Baker, Milan Bimali, Luis Carrillo, Archana Sachedina, Daisy Alapat, Md Shadiqul Hoque, Mathew Kottarathara, Richa Parikh, Amani Erra, Angel A Mitma, Pankaj Mathur, Yetunde Ogunsesan, Lakshmi Yarlagadda, Sravani Gundarlapalli, Sharmilan Thanendrarajan, Maurizio Zangari, Frits Van Rhee, Guido Tricot, Carolina Schinke
Not available.
-
Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial. Haematologica (IF 9.941) Pub Date : 2021-08-12 Cecilia Becattini, Rupert Bauersachs, Giorgio Maraziti, Laurent Bertoletti, Alexander Cohen, Jean M Connors, Dario Manfellotto, Antonio Sanchez, Benjamin Brenner, Giancarlo Agnelli
The effect of renal impairment (RI) on risk of bleeding and recurrent thrombosis in cancer patients treated with direct oral anticoagulants for venous thromboembolism (VTE) is undefined. We run a prespecified analysis of the randomized Caravaggio study to evaluate the role of RI as risk factor for bleeding or recurrence in patients treated with dalteparin or apixaban for cancer-associated VTE. RI was
-
One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non-identical family donors. Haematologica (IF 9.941) Pub Date : 2021-08-12 Dietger Niederwieser, Helen Baldomero, Nosa Bazuaye, Caitrin Bupp, Naeem Chaudhri, Selim Corbacioglu, Alaa Elhaddad, Cristóbal Frutos, Sebastian Galeano, Nada Hamad, Amir Ali Hamidieh, Shahrukh Hashmi, Aloysius Ho, Mary M Horowitz, Minako Iida, Gregorio Jaimovich, Amado Karduss, Yoshihisa Kodera, Nicolaus Kröger, Regis Péffault de Latour, Jong Wook Lee, Juliana Martínez-Rolón, Marcelo C Pasquini, Jakob
The Worldwide Network of Blood and Marrow Transplantation (WBMT) pursues the mission of promoting hematopoietic cell transplantation (HCT) for instance by evaluating activities through member societies, national registries and individual centers. In 2016, 82,718 first HCTs were reported from 1662 HCT teams in 86 of the 195 World Health Organization member states representing a global increase of 6
-
Thrombotic thrombocytopenic purpura and other immune mediated blood disorders following SARS-CoV-2 vaccination. Haematologica (IF 9.941) Pub Date : 2021-08-12 Pier Mannuccio Mannucci
Not available.
-
Thrombotic thrombocytopenic purpura and other immune mediated blood disorders following SARS-CoV-2 vaccination. Haematologica (IF 9.941) Pub Date : 2021-08-12 Pier Mannuccio Mannucci
Not available.
-
Immune-mediated thrombotic thrombocytopenic purpura following Pfizer-BioNTech COVID-19 vaccine Haematologica (IF 9.941) Pub Date : 2021-08-12 Gaetano Giuffrida,Annalisa Condorelli,Mary Ann Di Giorgio,Uros Markovic,Roberta Sciortino,Daniela Nicolosi,Francesco Di Raimondo
-
Fatal exacerbation of ChadOx1-nCoV-19-induced thrombotic thrombocytopenia syndrome after initial successful therapy with intravenous immunoglobulins - a rational for monitoring immunoglobulin G levels. Haematologica (IF 9.941) Pub Date : 2021-08-12 Jonathan Douxfils,Caroline Vayne,Claire Pouplard,Thomas Lecompte,Julien Favresse,Florence Potier,Emy Gasser,Valérie Mathieux,Jean-Michel Dogné,Yves Gruel,Jérôme Rollin,François Mullier
-
One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non-identical family donors. Haematologica (IF 9.941) Pub Date : 2021-08-12 Dietger Niederwieser,Helen Baldomero,Nosa Bazuaye,Caitrin Bupp,Naeem Chaudhri,Selim Corbacioglu,Alaa Elhaddad,Cristóbal Frutos,Sebastian Galeano,Nada Hamad,Amir Ali Hamidieh,Shahrukh Hashmi,Aloysius Ho,Mary M Horowitz,Minako Iida,Gregorio Jaimovich,Amado Karduss,Yoshihisa Kodera,Nicolaus Kröger,Regis Péffault de Latour,Jong Wook Lee,Juliana Martínez-Rolón,Marcelo C Pasquini,Jakob Passweg,Kristjan Paulson
The Worldwide Network of Blood and Marrow Transplantation (WBMT) pursues the mission of promoting hematopoietic cell transplantation (HCT) for instance by evaluating activities through member societies, national registries and individual centers. In 2016, 82,718 first HCTs were reported from 1662 HCT teams in 86 of the 195 World Health Organization member states representing a global increase of 6
-
Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial. Haematologica (IF 9.941) Pub Date : 2021-08-12 Cecilia Becattini,Rupert Bauersachs,Giorgio Maraziti,Laurent Bertoletti,Alexander Cohen,Jean M Connors,Dario Manfellotto,Antonio Sanchez,Benjamin Brenner,Giancarlo Agnelli
The effect of renal impairment (RI) on risk of bleeding and recurrent thrombosis in cancer patients treated with direct oral anticoagulants for venous thromboembolism (VTE) is undefined. We run a prespecified analysis of the randomized Caravaggio study to evaluate the role of RI as risk factor for bleeding or recurrence in patients treated with dalteparin or apixaban for cancer-associated VTE. RI was
-
Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease status. Haematologica (IF 9.941) Pub Date : 2021-08-12 David Baker,Milan Bimali,Luis Carrillo,Archana Sachedina,Daisy Alapat,Md Shadiqul Hoque,Mathew Kottarathara,Richa Parikh,Amani Erra,Angel A Mitma,Pankaj Mathur,Yetunde Ogunsesan,Lakshmi Yarlagadda,Sravani Gundarlapalli,Sharmilan Thanendrarajan,Maurizio Zangari,Frits Van Rhee,Guido Tricot,Carolina Schinke
Not available.
更新日期：2021-10-14
京公网安备 11010802027423号